Loading...
Pancreatic neuroendocrine cancers, which can progress slowly and have a long natural history, represent a more therapy-responsive subset of these malignancies. The past decade has seen the approval of a number of new agents beyond long-acting somatostatin analogue therapy, including everolimus, sunitinib, and lutetium LU 177 dotatate.
Investigators from China now report results of the SANET-p trial, an industry-sponsored randomized, double-blind, placebo-controlled, phase III study comparing oral surufatinib (a tyrosine kinase inhibitor targeting VEGFR1–3, FGFR, and macrophage colony stimulating factor 1) versus placebo in 172 patients with pancreatic neuroendocrine cancers and disease progression on no more than two prior systemic therapies…